REEVES v. MERCK & CO., INC

CourtDistrict Court, E.D. Pennsylvania
DecidedAugust 8, 2023
Docket2:21-cv-00976
StatusUnknown

This text of REEVES v. MERCK & CO., INC (REEVES v. MERCK & CO., INC) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
REEVES v. MERCK & CO., INC, (E.D. Pa. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: ZOSTAVAX (ZOSTER VACCINE LIVE) MDL No. 2848 PRODUCTS LIABILITY LITIGATION CIVIL ACTION NO.: 2:18-md-02848-HB

THIS DOCUMENT RELATES TO:

James Amundson and Mona Amundson v. Merck & Lynn Garden v. Merck & Co., Inc., et al., Co., Inc., et al., Civil Action No. 2:21-cv-01272 Civil Action No. 2:21-cv-01267 Larry Giese and Rebecca Fitzpatrick v. Merck & Co., Clinton Ashby and Kathleen Ashby v. Merck & Co., Inc., Inc., et al., et al., Civil Action No. 2:21-cv-01274 Civil Action No. 2:21-cv- 03003 Sandra Grimmett and George Grimmett v. Merck & Co. Kirby Balthrop v. Merck & Co., Inc., et al., Inc., et al., Civil Action No. 2:21-cv-01602 Civil Action No. 2:21-cv-03005

James Bleyer v. Merck & Co., Inc., et al., Edith Hagen v. Merck & Co., Inc., et al., Civil Action No. 2:22-cv-01035 Civil Action No. 2:21-cv-1275

Dorothea Booth v. Merck & Co., Inc., et al., Samuel Hamm v. Merck & Co., Inc., et al., Civil Action No. 2:21-cv-03927 Civil Action No. 2:21-cv-04341

Diane Bouffard v. Merck & Co., Inc., et al., Carol Hermanowski v. Merck & Co., Inc., et al., Civi Civil Action No. 2:21-cv-01600 Action No. 2:21-cv-01276

Pamela Brower v. Merck & Co., Inc., et al., Audrey Johnson v. Merck & Co., Inc., et al., Civil Action No. 2:21-cv-01268 Civil Action No. 2:21-cv-01277

Linda Caudle and William Caudle v. Merck & Co., Donna Johnson v. Merck & Co., Inc., et al., Inc., et al., Civil Action No. 2:21-cv-04342 Civil Action No. 2:21-cv- 01269 Katherine Jones and Theodore Jones v. Merck & Co., Ernest Charles v. Merck & Co., Inc., et al., Inc., et al., Civil Action No. 2:21-cv-00977 Civil Action No. 2:21-cv-01878

Midge Deverin and Bernard Deverin v. Merck & Deborah King-Kzaley and Robert Kzaley v. Merck & Co., Inc., et al., Co., Inc., et al., Civil Action No. 2:21-cv-01270 Civil Action No. 2:21-cv-01278

Marcia Federico v. Merck & Co., Inc., et al., Harry Krause and Karen Krause v. Merck & Co., Inc., Civil Action No. 2:21-cv-01271 et al., Civil Action No. 2:21-cv- 00978 Elaine Levin v. Merck & Co., Inc., et al., Carol Parker v. Merck & Co., Inc., et al., Civil Action No. 2:22-cv-00140 Civil Action No. 2:21-cv-03550

Nina Lociero-Scala and Daniel Scala v. Merck & Lori Petersen and Kent Petersen v. Merck & Co., Inc., Co., Inc., et al., et al., Civil Action No. 2:21-cv-05493 Civil Action No. 2:21-cv- 03004

Enoc Lopez and Judith Burgos v. Merck & Co., Inc., et Lisa Reeves and Paul Fasseel v. Merck & Co., Inc., al., et al., Civil Action No. 2:22-cv- 01036 Civil Action No. 2:21-cv- 00976

Michael Marburger and Sharron Marburger Joel Sinden v. Merck & Co., Inc., et al., v. Merck & Co., Inc., et al., Civil Action No. 2:21-cv-04345 Civil Action No. 2:21-cv-03928 Verna Srnick and Peter Srnick v. Merck & Co., Inc., et Kim Holben, as Executor of the Estate of Joyce al., Marquardt (deceased) v. Merck & Co., Inc., et al., Civil Action No. 2:21-cv- 01281 Civil Action No. 2:21-cv-05497 Regina Thompson v. Merck & Co., Inc., et al., Nancy Marr and Ethan Marr v. Merck & Co., Inc., et al., Civil Action No. 2:21-cv-01282 Civil Action No. 2:22-cv-00141 Stan Udhiri and Solange de Mendonca Tavares v. Sandra McBride and David McBride v. Merck & Merck & Co., Inc., et al., Co., Inc., et al., Civil Action No. 2:21-cv-01283 Civil Action No. 2:21-cv-04343 Leonard Whitney and Patricia Whitney v. Merck & Walter Milanicz v. Merck & Co., Inc., et al., Co., Inc., et al., Civil Action No. 2:21-cv-01279 Civil Action No. 2:21-cv-01284

Kathleen Mintari v. Merck & Co., Inc., et al., Carol Withycombe v. Merck & Co., Inc., et al., Civil Action No. 2:21-cv-01280 Civil Action No. 2:21-cv-01285

Debbie Neil and Johnnie Neil v. Merck & Co., Inc., Pamela Yates and Walter Yates v. Merck & Co., Inc., et et al., al., Civil Action No. 2:21-cv- 04344 Civil Action No. 2:21-cv- 01286

MEMORANDUM IN SUPPORT OF PRETRIAL ORDER NO. 491 Bartle, J. August 8, 2023 Before the court is the omnibus motion of defendants Merck & Co., Inc. and Merck Sharp & Dohme LLC (“Merck”) to dismiss without prejudice 42 actions in this MDL for insufficient service of process under Rule 12(b)(5) of the Federal Rules of Civil Procedure. Merck maintains that plaintiffs failed timely to effect service of the complaints in accordance with Rule 4(m) of the Federal Rules of Civil Procedure (Doc. # 1216). These actions were all filed by one

law firm. Plaintiffs have countered with a motion for extension of time to make service (Doc. # 1218). These 42 cases were filed between March 1, 2021 and March 18, 2022. Merck had notice of these filings shortly after they were docketed, and counsel to Merck entered an appearance in each. Service of process, however, had still not been made as of June 9, 2023. On that date, counsel for Merck wrote to plaintiffs’ counsel identifying 43 cases1 where service had not been made during the 90-day period required under Rule 4(m). Merck’s counsel asked plaintiffs’ counsel to advise him by June 16, 2023 “whether you believe some circumstance exists in any of these cases that constitutes good cause to extend the time for

service, and, if so, what that circumstance is.” Failure to provide good cause, Merck’s counsel continued, would result in the filing of motions to dismiss. Plaintiffs’ counsel responded that she had been under the impression that the cases had been properly served but upon investigation learned that they had not. She acknowledged that “inadvertence of counsel” does not constitute good cause but

1. One of the 43 cases has now been dismissed and is not in dispute here. argued that good cause is not necessary for the court to exercise its discretion to grant an extension of time. Among other arguments, she referenced the fact that Merck knew about

the actions when they were filed and waited for up to more than two years to raise the issue. Some of the plaintiffs, she maintains, will be prejudiced because the statute of limitations may have expired while Merck will suffer no prejudice. Within days after receiving the June 9 letter, plaintiffs’ counsel effected service in all 42 actions. Merck’s pending motion to dismiss followed shortly thereafter on July 7, 2023 as did plaintiffs’ motion for an extension of time for service. The cases in this MDL are divided into three categories. Group A consisted of some 1,195 cases where service had been made and plaintiffs claimed that the sole injury suffered was contracting shingles after being injected with the

Zostavax vaccine. Group C are the cases involving hearing loss. Group B represents the remaining cases where other injuries are alleged. Of the 42 subject cases, 34 fall under Group A while the remaining eight fit into Group B.2

2. Plaintiffs’ counsel asserted that 32 of the subject cases were part of Group A, while defendants contended that 36 of them fell into that Group. The court has reviewed the complaints of the subject cases and determined that in 34 cases plaintiffs allege that they suffered solely from shingles. Pursuant to procedures worked out with the parties, five Group A Bellwether cases were selected for trial. Prior to trial, however, the court granted summary judgment in favor of

Merck because plaintiffs’ expert did not meet the standard under Rules 702 and 703 of the Federal Rules of Evidence and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). See In re Zostavax (Zoster Vaccine Live) Prod. Liab. Litig., 579 F. Supp.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
REEVES v. MERCK & CO., INC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/reeves-v-merck-co-inc-paed-2023.